Abstract: . . .  aregreater, making it difficult to reach definitive conclusions about whether catheteriza- tion rates in France lag behind those in the United States and Israel. 12. McClellan and Kessler, A GlobalAnalysisof TechnologicalChangeinHealth Care. 13. Early trialsoftPAversusstreptokinase detected no difference in effects.How- ever,trialsin the1990s evaluated more rapid and sophisticated delivery proto- cols suggested . . .
. . .  Event Rates, and Coronary Heart Disease Mortality acr oss the WHO MONICA Project Populations, Lancet 355 (2000): 688700. 16. Tunstall-Pedoe et al., Estimation of the Contribution of Changes. 42 HEART ATTACK CARE H E A L T H A F F A I R S V o l u m e 2 0 , N u m b e r 3 C r o s s - N a t i o n a l C o m p a r i s o n s  . . .
. . .  countrys population. How- ever, it is clear that ifhigh-quality care requires rapid innovation and diffusion of valuable high-cost as well as low-cost treatments, qual- ity of care may differ greatly around the world, and national health policies may influence quality in important ways. The formal evidence from clinical trials on the effects of such high-cost intensive procedures is and will likely . . .
. . .  Improving Survival, Event Rates, and Coronary Heart Disease Mortality acr oss the WHO MONICA Project Populations, Lancet 355 (2000): 688700. 16. Tunstall-Pedoe et al., Estimation of the Contribution of Changes. 42 HEART ATTACK CARE H E A L T H A F F A I R S V o l u m e 2 0 , N u m b e r 3 C r o s s - N a t i o n a l C o m p a r i s o . . .
. . .  Technological Change Around The World: Evidence From Heart Attack Care Supply side incentives to curtail health care spending are closely linked with trends in the use of costly treatments. by the Technological . . .
. . .  LectureCar- diovascular Medicine at the Turn of th e Millenium, New England Journal of Medicine 337, no. 19 (1998): 13601369 ; and D.M. Cutler et al., Are Medical Prices Declining? Evidence for Heart Attack Treatments, Quarterly Journal of Economics 113, no. 4 (1998): 9911024. 4. Most countries were able to provide national data or data from large regional  . . .
. . .  Study, Journal of the American College of Cardiology 33, no. 7 (1999): 18791885. 14. For example, the protocol for Montreal General Hospital states that the groups most likely to benefit from tPA should get it. In a Quebec registry of AMI collected in 19951996 amongforty-four Quebec acutecare hospitalsand 3,741 patients with AMI of whom 1,357 received thrombolytic therapy, 68.2 percent . . .
--3000,7,214,3350,57864